Knowledge Capital, Intangible Assets, and Leverage: Evidence from U.S. Agricultural Biotechnology Firms by Sporleder, Thomas L. & Moss, Leeann E.
￿ 2004 International Food and Agribusiness Management Association (IAMA). All rights reserved. 26
International Food and Agribusiness Management Review
Volume 7, Issue 2, 2004
Knowledge Capital, Intangible Assets, and Leverage: Evidence
from U.S. Agricultural Biotechnology Firms
Thomas Sporleder ai and LeeAnn Moss b
a Professor, AED Economics, Ohio State University, Columbus,Ohio.
b Assistant Professor, AED Economics, Ohio State University, Columbus,Ohio.
Abstract
Agricultural biotechnology firms are high technology companies.  Firms in general,
and high technology firms in particular, are a set of both assets in place and growth
opportunities.  This has important implications for managerial decision-making.
Knowledge capital motivates exploitation of growth options, which affects firm cash
flow. In turn, the level and volatility of firm cash flow influences firm financing
decisions. Previous studies suggest that knowledge capital can influence both the
location and capital structure of firms in the biotechnology industry.  However,
empirical analysis has not extended to agricultural biotechnology firms.  This
research helps in understanding the role of knowledge capital and other intangible
assets in capital structure decisions of U.S. agricultural biotechnology firms.
Quantitative results indicate that leverage is negatively related to growth and non-
debt tax shields.  Asset tangibility, size, profitability, and uniqueness are positively
related to leverage. Using various characterizations of leverage, our models explain
up to approximately 75% of the variation in leverage.  Empirically generated
elasticities buttress the importance of intangible assets such as knowledge capital
and tax shields in capital structure choice.  This analysis adds a significant new
component to understanding the financing decisions of agricultural biotechnology
firms.
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Introduction
Technological advances, better management practices, and improved production
inputs are driving forces behind the substantial productivity gains experienced by
the U.S. agricultural sector. Agricultural biotechnology plays an integral role, and
as such, has profoundly influenced the face of U.S. farming, food processing, and
food consumption.  Agricultural biotechnology firms participate in a food system
where rivalry continues to shift from tangible to intangible assets such as
knowledge capital.
Biotechnology firms are characteristic of high technology companies.  Firms in
general, and high technology firms in particular, are a set of both assets in place
and growth opportunities (Myers, 1977; Myers and Majluf, 1984; Rajan and
Zingales, 1995).  Liu (2001) reminds us that the “essence of a firm in the new
economy is its ability to create, transfer, assemble, integrate, protect, and exploit
knowledge capital. Knowledge capital underpins competences, and competences
underpin the firm’s product and service offering to the market”  (p. 1).  This has
important implications for managerial decision-making.  Knowledge capital
motivates exploitation of growth options, which affects firm cash flow. In turn, the
level and volatility of firm cash flow fundamentally influences firm financing
decisions.
Firm capital structure has received extensive theoretical and empirical attention,
including the role of intangible assets on optimal leverage (e.g., Rajan and Zingales,
1995).  A recent study explores the characteristics and growth of U.S. biotechnology
firms (Zucker, Darby, and Brewer, 1998).  Their findings reveal a connection
between the location and growth of intellectual capital and that of U.S.
biotechnology firms.  It is apparent from these studies that knowledge capital can
influence both the location and capital structure of biotechnology firms. Liu (2001)
studied the interaction among biotechnology firms’ knowledge capital, growth
opportunities, earnings dynamics, and optimal leverage.  Results suggest that
investments in research and development and knowledge capital are related to
leverage.  However, the empirical analysis has not extended to agricultural
biotechnology firms.
The research reported in this manuscript is motivated by a desire to understand the
role of knowledge capital and other intangible assets in capital structure decisions
of U.S. agricultural biotechnology firms.  The objective is to better understand the
role that knowledge capital and other intangible assets has on their debt versus
equity financing decisions.  The remainder of the paper is organized as follows.
Background and a brief literature review are presented first, followed by a
description of our data and empirical model, and a discussion of the results derived
from it. The paper ends with concluding remarks and suggestions for additional
research in this area.T. Sporleder and L. Moss / International Food and Agribusiness Management Review Volume 7, Issue 2, 2004
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Background and Literature
Several categories of firms operate in the agricultural biotechnology industry.
Dedicated biotechnology companies (DBCs) are those firms primarily engaged in
biotechnology research activities and are often small, private, start-up companies
early in their life cycle (Sporleder, 1999).  Smaller DBCs often develop “platform
technologies” that position the firm for merger, acquisition, or initial public offering.
Though innovative, they do not have the financial or human capital necessary to
fund developmental research and commercialize new products.  Strategic
partnering with larger major corporations with complementary business assets can
result.  Second, certain major corporations have significant investments in
biotechnology though their revenue stream is not fundamentally dependent upon
biotechnology-based products or services.  Pharmaceutical companies are a third
firm type but are primarily oriented toward the human health market rather than
toward food or agriculture.  The focus of this study is on U.S.-based DBCs.
The capital structure literature has become well developed over the past four
decades. 1  More recently, knowledge is increasingly becoming recognized as both a
strategic and valuable asset of a firm, and its management is emerging as a
potential source of competitive advantage in contemporary analyses (Connor and
Prahalad, 2002; Grant, 2002; Hudson, 1993; Morey, Maybury, and Thuraisingham,
2000; Sporleder and Moss, 2002; Nonaka and Takeuchi, 1995).  Using the logic of
the various strains of capital structure theory, one may conclude that industries or
firms with a large proportion of knowledge assets should be less levered in that
these assets are less redeployable and may have lower liquidation value.  However,
the interaction among knowledge capital and capital structure largely remains an
unanswered theoretical and empirical question, particularly for agricultural
biotechnology firms.
In their study of 751 biotechnology firms Zucker, Darby and Brewer found that both
DBC start-ups and expansion subsidiaries of incumbent firms locate around
intellectual human capital, namely “star” scientists who are significant contributors
to the basic science.  They also explored the role of venture capital in location choice
since the availability of venture capital funding is believed to play a vital role in
new firm entry (Lerner, 1995).  The numbers of star scientists, top-quality
universities, faculty with federal support and venture capital firms are positive and
statistically significant predictors of both the stock value of biotechnology firms
operating in a region and the number of new start-ups.  Interestingly, venture
capital firms had a strong positive effect only when other measures of intellectual
human capital (i.e., universities, star scientists and federal funding) were
eliminated from the model.  The presence of venture capital firms may in fact proxy
for more direct measures of intellectual capital in that these firms tend to develop
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around the scientists and institutions that they serve.  However, other than
describing the sources of funding, these authors did link between capital structure
and knowledge assets at the firm level.
A recent study explores the interaction among U.S. biotechnology firms’ knowledge
capital, growth options, earnings, and capital structure (Liu, 2001).  The author’s
theoretical model suggests a positive relationship among knowledge capital and
leverage, which contrasts with most previous studies.  The empirical results support
further that debt ratios are positively related to knowledge capital measures such
as research and development (R&D) investment (in the absence of better measures),
citation-weighted patent counts, and claim-weighted patent counts.  Additionally,
this study is the first to apply several classical determinants of capital structure to
biotechnology firms.  Results suggest that leverage is positively related to firm size
and asset tangibility and negatively related to profitability and uniqueness.
One study has investigated the role of intellectual capital and venture capital
financing on the location choice of agricultural biotechnology firms (Sporleder,
Moss, and Nickles, 2002).  It suggests that the location choice (i.e., state) of
agricultural DBCs is determined primarily by R&D funding.2  Total R&D funding
per million people can proxy for the general intellectual human capital of a region
as evidenced through its science and higher educational environment.  Venture
capital has a positive though statistically insignificant influence on location choice,
while the size of a state’s economy and its dependence on agriculture has negative
and statistically insignificant effects. However, what determines the capital
structure of agricultural biotechnology firms remains an unexplored empirical
question. Our study is a preliminary effort toward this goal.
Empirical Model
The determinants of capital structure are explored for publicly traded U.S.
agricultural biotechnology firms using COMPUSTAT data. The data set includes
6,671 firm-year observations from 748 firms for the time period 1980 through 2000,
where agricultural biotechnology firms are identified by a total of eighteen six-digit
NAICS codes.3  Consistent with previous empirical studies, various measures of
firm leverage are considered and contrasted in the analysis.  The influence of
growth, size, profitability, non-debt tax shields, the uniqueness of the firm’s assets,
and intangible assets such as knowledge capital are explored using ordinary least
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squares regression. The capital structure of agricultural biotechnology firms is
modeled as follows:
LEVERi   =  a + b1 TANGi + b2 NDTSi + b3 GROWi  + b4 UNIQi + b5 SIZEi
         + b6 PROFITi   + ei
where:
LEVERi = Firm leverage, measured as: (i) total debt divided by total assets
(“Leverage 1”)4; (ii) total debt divided by the sum of total debt
and common equity (market value) (“Leverage 2”); and (iii) total
liabilities divided by total assets (“Leverage 3”).
TANGi = Tangibility of assets (inventory plus gross plant and equipment
divided by total assets);
NDTSi =  Non-debt tax shields (operating income less interest expense
less tax payments divided by total assets);
GROWi = Firm growth (percentage change in total assets);
UNIQi =  Uniqueness of the firm’s assets (selling and administrative
expenses divided by total assets);
SIZEi = Firm size (natural logarithm of net sales);
PROFITi =  Firm profitability (earnings before interest, taxes and
depreciation (EBITDA) divided by total assets);
As indicated, three different leverage measures are considered.  Leverage 1
measures the ratio of debt used the finance the firm’s assets based on book values,
while Leverage 2 is based on market value. Leverage 3 represents the most
expansive definition in that total liabilities include items only indirectly related to
financing (e.g., accounts payable).  As such, it serves as a proxy for the residual to
shareholders upon firm liquidation.
The independent variables are measured in a manner most appropriate in terms of
their overall explanatory power for this sample of firms.5  First, consensus exists
that the characteristics of a firm’s assets influences its capital structure (e.g.,
Williamson, 1988; Long and Malitz, 1985; Rajan and Zingales, 1995).  Asset
tangibility and leverage should be positively related in that tangible assets are both
readily collateralized and liquidated/redeployed at market value. High technology
firms’ knowledge capital is relatively non-redeployable, hence, we expect companies
with greater knowledge assets to be less levered.
Financing decisions may be persuaded by the tax benefits of debt, if the firm has
enough taxable income to support debt. In contrast, other non-debt tax shields such
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as investment tax credits, amortization, and depreciation deductions may mitigate
this incentive.  Empirical studies of the influence of non-debt tax shields on leverage
are numerous, though results are conflicting (Bradley, Jarrell and Kim, 1984;
Harris and Raviv, 1991; Titman and Wessels, 1988; Banerjee, Heshmati and
Wihlborg, 2000).  Consistent with recent studies of other publicly traded firms, we
expect non-debt tax shields to be negatively related to leverage for agricultural
biotechnology firms.
Most of the capital structure literature suggests that growth and leverage are
negatively related, though for various reasons.  Based on the underinvestment
problem articulated by Myers and Majluf (1984), firms who anticipate a high rate of
future growth should rely on a greater degree of equity capital.  Or, high growth
companies have greater abilities to invest less and, as a result, extract wealth from
their shareholders (Titman and Wessels, 1988).  Growth can be measured as either
the percentage change in total assets from year to year (i.e., actual growth in firm
size) or as market-to-book value (i.e., growth opportunities enabled by intangible
assets like managerial prowess).  The authors have chosen the former measure and
expect a negative relationship between firm growth and leverage.
Uniqueness represents the differences among firms that may result in competitive
advantage.  Titman and Wessels (1988) argue that firms that provide unique or
specialized products or services will experience thinner markets when liquidating
with lower asset values recoverable by their lenders.  Uniqueness is commonly
measured as the ratio of either R&D expenditures or selling and administrative
expenses to total assets.  Following the literature, we anticipate that uniqueness
and the firm’s debt ratio will be negatively related and use selling and
administrative expenses as a proxy for uniqueness.
Previous research is divided on the role of firm size and leverage.  Larger firms are
more diversified and have a lower probability of bankruptcy.  They typically have
lower costs when issuing debt or equity in comparison to their smaller counterparts.
Debt tends to be less expensive for smaller firms in comparison to equity, and as a
result, small firms may support higher leverage. However, larger firms possess
greater debt carrying capacity suggesting greater leverage ratios.  Consistent with
previous studies, we consider the natural logarithm of net sales as our size
measure.  A priori, the relationship among size and leverage for agricultural
biotechnology firms in our sample is indeterminate.
Despite different theoretical arguments (e.g., Myers and Majluf, 1984; Titman and
Wessels, 1988; and Jensen, 1986), the empirical evidence unambiguously suggests a
negative relationship between profitability and firm capital structure.  Firms prefer
internal to external financing, and more profitable firms have more internal capital
available.  The present authors use the ratio of net income to total assets as a
measure of profitability.T. Sporleder and L. Moss / International Food and Agribusiness Management Review Volume 7, Issue 2, 2004
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Results and Discussion
Summary statistics for the model variables are presented in Table 1.  Leverage
means are distinctly different across the three definitions of leverage considered in
this study.  The sample displays a wide degree of variability in the explanatory
variables of interest. Notably, 52.32 percent of these firms’ assets are tangible on
average, though the ratio of tangible to total assets ranges from zero to 99.48
percent.  On average, these 748 firms are not growing in size and are not profitable
at this stage in their life cycles.
Table 1: Summary Statistics for Model Variables
Variable Mean S.D. Maximum Minimum
LEVERAGE 1 0.1754 0.8514 50.7273 0
LEVERAGE 2 0.2600 2.2305 157.3200 0
LEVERAGE 3 0.7251 4.9180 255.6667 0
TANG 0.5232 1.3929 99.4762 0
NDTS -0.4040 2.8616 3.0566 -158.6667
GROW -0.0176 1.8973 1 -106.5000
UNIQ 0.4526 2.5507 154.0000 0
SIZE 2.4026 2.8201 10.6057 -6.9078
PROFIT -0.3946 2.8196 4.7800 -154.0000
Table 2 reports the results of the regression models for each leverage
characterization.  Consistent with results from previous studies using market
value-based characterizations of leverage, the overall performance of the Leverage 2
model is poor.  Market values of common equity, particularly during the time period
considered in this study, may be driven increasingly by market-related factors (e.g.,
investor optimism, information) that escape explanation in our model.
The Leverage 1 model, where leverage is measured as the ratio of total debt to total
assets, explains about 40 percent of the variation in capital structure.  The
coefficients behave as anticipated, except growth and profitability.  In this model,
growth and leverage are positively related which is counterintuitive and
inconsistent with the other leverage models considered in this study.  This model
suggests further that profitability and leverage are positively related, which is an
unanticipated result.  However, the sign of the profitability variable in consistently
positive across all three models for this sample of firms.
Finally, the Leverage 3 model, with leverage measured as the ratio of total
liabilities to total assets, explains approximately 75 percent of the variation in
capital structure.  Moreover, all coefficients are statistically significant at the 1
percent level.  In contrast to our a priori expectations, uniqueness and leverage are
positively related. We expect that firms with more unique products are more likelyT. Sporleder and L. Moss / International Food and Agribusiness Management Review Volume 7, Issue 2, 2004
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Table 2: OLS Regression – Leverage of U.S. Agricultural Biotechnology Firms









Intercept   0.0180
     (0.0114)
  0.2381***
     (0.0385)
  -0.6211***
     (0.0422)
TANG   0.1606***
     (0.0088)
  0.0697**
     (0.0297)
  1.2051***
     (0.0326)
NDTS   -0.4415***
     (0.0212)
  -0.1702**
     (0.0716)
  -1.6333***
     (0.0786)
GROW   0.0473***
     (0.0045)
  -0.0027
     (0.0153)
  -0.1110***
     (0.0168)
UNIQ   -0.3764***
     (0.0072)
  0.0182
     (0.0243)
  0.1559***
     (0.0266)
SIZE   0.0346***
      (0.0031)
  -0.0065
     (0.0103)
  0.0625***
     (0.0113)
PROFIT   0.0423*
     (0.0230)
  0.1926**
     (0.0779)
  0.4226***
     (0.0855)
Adj. R2   =
0.4009




Adj. R2   =
0.0010




Adj. R2   =
0.7526




a Standard errors are in parenthesis. Asterisks indicate significance at the 10% (*), 5% (**), and 1%
levels (***), respectively.
to spend more to advertise and promote their market offerings.  However, commonly
used measures of uniqueness such as ours have some well-documented
shortcomings (e.g., our measure can be related to both non-debt tax shields and
collateral value) and better measures continue to be both theoretically and
empirically explored (Rajan and Zingales, 1995; Banerjee, Heshmati, and Wihlborg,
2000).  Thus, little weight is given to the performance of this indicator in any of the
three models.
The consistently positive relationship between profitability and leverage across all
models is puzzling.  If firms do in fact follow a pecking order, the authors expect
internal finance to be preferred over debt, which in turn is more favorable to new
equity issues.  More profitable firms, ceteris paribus, have more available internal
capital and can chose to rely less on debt capital.  Why do more profitable publiclyT. Sporleder and L. Moss / International Food and Agribusiness Management Review Volume 7, Issue 2, 2004
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traded agricultural biotechnology firms use more debt?6  Perhaps the answer lies in
the industry context.  No previous capital structure studies, except for Liu (2001),
considered high technology firms alone.  Though Liu (2001) found a negative
relationship among the profitability of U.S.-based biotechnology firms and their
debt ratios, this relationship generally was weak and statistically insignificant.
Since many biotechnology firms are start-ups with little or no operating income, the
result from the present analysis is not too surprising.
Elasticity estimates from the Leverage 3 model are presented in Table 3. Both
growth and uniqueness influence leverage very little.  In contrast, firm size has the
largest effect. Every 1 percent increase in firm size results in a 3.3 percent increase
in firm leverage.  Tangibility and non-debt tax shields have modest elasticities at
0.87 and 0.91, respectively.









Quantitative results indicate that growth, non-debt tax shields, and intangible
assets are negatively related to firm leverage. In contrast, size, profitability, and
uniqueness are positively related.  These results generally are reasonably consistent
with previous studies of firms in other industries. In fact, the model explains
approximately 75% of the variation in leverage among agricultural biotechnology
firms.  Other studies, which apply similar models to other firm types, have notably
less explanatory power.
The empirical evidence presented here unambiguously suggests a negative
relationship among profitability and firm capital structure.  Evidence here suggests
that agricultural biotechnology firms prefer internal (equity) to external (debt)
financing, and more profitable firms have more internal capital available.  The
present authors use the ratio of net income to total assets as a measure of
profitability.
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Empirically generated elasticities buttress the importance of intangible assets and
tax shields in capital structure choice add a significant new component to
understanding agricultural biotechnology firms.  The results have implications for
both managerial decision-making and financing for these companies.  Debt
(external) capital is disciplined by market forces whereas equity (internal) capital is
not subjected to the same discipline.  Agricultural biotechnology firms prefer
internal to external financing.
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